共 50 条
- [1] Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 5545 - 5550
- [2] Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M [J]. GLOBAL MEDICAL GENETICS, 2021, 08 (04): : 133 - 134